ST. LOUIS--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today reported positive efficacy results in the Phase 3 clinical trial for MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. MNK-155 met the primary endpoint in this study.
Help employers find you! Check out all the jobs and post your resume.
